Amphastar Pharmaceuticals (AMPH) Rebounds On Momentum, Is The 20% Premium Already Too Rich?

Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent price moves, with the share price closing at US$27.39 and short term returns outpacing its longer term performance profile.

For Amphastar Pharmaceuticals, the recent 24.44% 30-day share price return and 35.73% 90-day share price return point to building momentum, even though the 3-year total shareholder return declined 40.12% while the 5-year total shareholder return sits at 43.40%.

Compare Amphastar Pharmaceuticals with a hand picked set of peers by scanning our 16 high quality undiscovered gems that also combine established operations with room for fresh momentum.

Bulls point to Amphastar Pharmaceuticals’ recent rebound and ongoing revenue and net income growth, while bears flag the share price slide over three years. Which story do the current valuation numbers appear to support?

Most Popular Narrative: 20% Overvalued

The most followed valuation storyline currently puts Amphastar Pharmaceuticals’ fair value at $22.83, which sits below the last close at $27.39. That gap matters because it is built on detailed assumptions about competition, pricing pressure, and future earnings power.

The expectation that pricing pressure and increased competition, particularly in crucial products like glucagon and epinephrine, will intensify going forward is likely reflected in the stock's valuation. This could put continued downward pressure on both revenue and gross margins in the coming quarters and years.

See why 30 investors see Amphastar Pharmaceuticals as 20% overvalued.

Result: Fair Value of $22.83 (OVERVALUED)

Still, Amphastar Pharmaceuticals could surprise if its U.S. manufacturing expansion improves resilience and if the broader pipeline reduces reliance on a handful of key products.

Find out about the key risks to this Amphastar Pharmaceuticals narrative.

Another View: Amphastar Pharmaceuticals Through The P/E Lens

Analysts see Amphastar Pharmaceuticals as 20% overvalued at $27.39 versus a fair value of $22.83, yet the P/E picture looks softer. The current 14.8x earnings multiple is below the US pharmaceuticals average of 15.6x and well under a 23.3x peer group level.

The fair ratio also sits at 14.8x. This suggests limited upside if the market drifts toward that benchmark, but it also signals less downside if expectations cool further. For investors weighing all of this, the real question is which narrative eventually sets the tone for the share price.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Conflicting signals around Amphastar Pharmaceuticals are already on the table, so move quickly, review the full data set, and weigh both the 2 key rewards and 3 important warning signs.

Looking For More Amphastar Pharmaceuticals Style Investment Ideas?

If Amphastar Pharmaceuticals has you thinking harder about valuation and momentum, do not stop here. Quickly scan a few focused stock lists so you are not leaving potential opportunities on the table.

• Target resilient balance sheets and steady fundamentals by reviewing the list of solid balance sheet and fundamentals (25 results) that could handle tougher conditions without drama.
• Hunt for quality at a discount by using the 32 high quality undervalued stocks to spot companies where the price lags the underlying financial strength.
• Focus on stability and sleep-better-at-night holdings by running through the 30 resilient stocks with low risk scores that aim to keep surprises to a minimum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com